【摘要】：目的比較雙時相門冬胰島素50注射液與雙時相人胰島素50注射劑治療2型糖尿病的臨床療效及安全性。方法將112例口服二甲雙胍血糖控制不達標的2型糖尿病患者隨機分為對照組56例和試驗組56例。對照組予以0.4U·kg~(-1)雙時相人胰島素50,bid(早、晚餐前5 min),皮下注射;試驗組予以雙時相門冬胰島素50,早餐前30 min予以0.4 U·kg~(-1),晚餐前30 min予以0.2U·kg~(-1),皮下注射。2組患者均治療36周。比較2組患者的餐后2 h血糖(2 h PG)、可溶性細胞間黏附分子1(s ICAM~(-1))、可溶性血管細胞間黏附分子1(s VCAM~(-1))、單核細胞趨化蛋白~(-1)(MCP~(-1))和腫瘤壞死因子(TNF-α)的水平,以及藥物不良反應(yīng)的發(fā)生情況。結(jié)果治療后,試驗組和對照組的2 h PG分別為(8.31±2.43),(11.08±2.43)mmol·L~(-1),差異有統(tǒng)計學(xué)意義(P0.05)。治療后,試驗組和對照組的s ICAM~(-1)分別為(229.82±7.61)和(249.45±8.05)μg·L~(-1),s VCAM~(-1)分別為(531.58±11.45)和(559.82±15.42)μg·L~(-1),MCP~(-1)分別為(371.46±9.76)和(399.64±12.85)μg·L~(-1);TNF-α分別為(12.05±1.18)和(15.81±1.76)μg·L~(-1),差異均有統(tǒng)計學(xué)意義(均P0.05)。2組患者的藥物不良反應(yīng)均以低血糖為主,試驗組和對照組的藥物不良反應(yīng)發(fā)生率分別為5.36%和14.29%,差異無統(tǒng)計學(xué)意義(P0.05)。結(jié)論與雙時相人胰島素50注射劑相比,雙時相門冬胰島素50注射液可顯著降低患者的2 h PG和血清s ICAM~(-1)、s VCAM~(-1)、MCP~(-1)、TNF-α的水平,且不增加藥物不良反應(yīng)的發(fā)生率。
[Abstract]:Objective to compare the clinical efficacy and safety of dual phase aspartate insulin 50 injection and dual phase human insulin 50 injection in the treatment of type 2 diabetes. Methods 112 patients with type 2 diabetes mellitus were randomly divided into control group (n = 56) and experimental group (n = 56). In the control group, 0.4 U kg~ (-1) human insulin was injected subcutaneously 5 min), before dinner. The experimental group was treated with double-phase aspartic insulin 50, 0.4 U kg~ (-1) 30 min before breakfast and 0.2 U kg~ (-1) 30 min before dinner. The patients in both groups were treated for 36 weeks. Two hours postprandial blood glucose (2 h PG), soluble intercellular adhesion molecule-1 (s ICAM~ (-1),) soluble vascular intercellular adhesion molecule-1 (sVCAM~ (-1),) was compared between the two groups. The levels of monocyte chemoattractant protein-1 (MCP~ (-1) and tumor necrosis factor (TNF- 偽), and the occurrence of adverse drug reactions. Results after treatment, the PG of the experimental group and the control group were (8.31 鹵2.43), (11.08 鹵2.43) mmol L ~ (-1), respectively. The difference was statistically significant (P0.05). After treatment, s ICAM~ (-1) was (229.82 鹵7.61) 渭 g L ~ (-1) and (249.45 鹵8.05) 渭 g L ~ (-1), s VCAM~ (-1) in the experimental group and the control group respectively (531.58 鹵11.45) and (559.82 鹵15.42) 渭 g L ~ (-1), respectively. MCP~ (-1) was (371.46 鹵9.76) 渭 g / L ~ (-1) and (399.64 鹵12.85) 渭 g / L ~ (-1), respectively. TNF- 偽 was (12.05 鹵1.18) 渭 g / L ~ (-1) and (15.81 鹵1.76) 渭 g / L ~ (-1), respectively (P0.05). The incidence of adverse drug reactions in the test group and the control group were 5.36% and 14.29%, respectively. The difference was not statistically significant (P0.05). Conclusion compared with the dual phase human insulin 50 injection, the serum s ICAM~ (-1), s VCAM~ (-1), MCP~ (-1), TNF- 偽) levels were significantly lower in the patients than in the two phase aspartate insulin 50 injection at 2 h after injection, and the levels of serum s ICAM~ (-1), s VCAM~ (-1), MCP~ (-1) and TNF- 偽) were significantly decreased. The incidence of adverse drug reactions was not increased.
【作者單位】： 重慶市急救醫(yī)療中心檢驗科;四川省人民醫(yī)院兒科;
【基金】：國家自然科學(xué)基金資助項目(81300238)
【分類號】：R587.1

【參考文獻】

相關(guān)期刊論文 前1條

1 王立坤;武雪亮;楊占清;張軍;史麗;楊瑞敏;王義成;;2型糖尿病患者血清抵抗素和瘦素及脂聯(lián)素水平與頸動脈斑塊的相關(guān)性研究[J];中國臨床藥理學(xué)雜志;2017年04期

【共引文獻】

相關(guān)期刊論文 前1條

1 楊麗;唐靜;候f ;;雙時相門冬胰島素50注射液治療2型糖尿病的臨床研究[J];中國臨床藥理學(xué)雜志;2017年15期

【二級參考文獻】

相關(guān)期刊論文 前2條

1 宋愛霞;紀蓉;劉俊峰;薛茜;;腦梗死患者血清生物標志物水平與頸動脈斑塊的相關(guān)性研究[J];中國臨床藥理學(xué)雜志;2016年03期

2 周小愛;朱綏;朱長遠;王筱t，

本文編號：2294467